Abstract: Novel N-methoxymethylated (MOM) pyrimidine (4−13) and pyrimidine-2,4-diones (15−17) nucleoside mimetics in which an isobutyl side-chain is attached at the C-6 position of the pyrimidine moiety were synthesized. Synthetic methods via O-persilylated or N-anionic uracil derivatives have been evaluated for the synthesis of N-1-and/or N-3-MOM pyrimidine derivatives with C-6 acyclic side-chains. A synthetic approach using an activated N-anionic pyrimidine derivative afforded the desired N,N-1,3-diMOM and N-1-MOM pyrimidines 4 and 5 in good yield. Introduction of fluorine into the side-chain was performed with DAST as the fluorinating reagent to give a N,N-1,3-diMOM pyrimidine 13 with a 1-fluoro-3-hydroxyisobutyl moiety at C-6. Conformational study of the monotritylated N-1-MOM pyrimidine 12 by the use of the NOE experiments revealed the predominant conformation of the compound to be one where the hydroxymethyl group in
Introduction
The pyrimidine moiety is a widespread heterocyclic unit which is found in several biologically active natural products, as well as synthetic pharmacophores with biological activities that show considerable therapeutic potential [1] [2] [3] [4] [5] . The structural diversity and biological importance of pyrimidines have made them attractive targets for synthesis over the years. For this reason numerous analogues and derivatives of pyrimidines have been synthesized and developed as pharmacologically active compounds or drugs [6, 7] .
Many N-substituted uracil derivatives have exhibited extremely diverse physiological activity [8] . It was shown that N- 1 and/ or N-3-alkylated pyrimidine derivatives had a wide range of antiviral activity [9] [10] [11] [12] [13] [14] . A large number of thymidine analogues and acyclic guanosine derivatives showed antiviral activities against herpes simplex virus type 1 (HSV-1) and 2 (HSV-2) [15] . The antiviral activity of these compounds is due to their selective and efficient in vivo activation through monophosphorylation by the viral enzyme [16, 17] . The monophosphates are converted to diphosphates, and then to the corresponding triphosphates by cellular enzymes. The triphosphates prevent viral replication by inhibition of the viral DNA polymerase [18] . The molecular basis of the therapy, which uses viral thymidine kinase (TK), is the difference in substrate specificity between the herpes viral TK and the human cellular isoenzyme. Therefore, HSV-1 TK in combination with nucleoside analogue as fraudulent substrates can be used as suicide enzymes in gene therapy of cancer [19] [20] [21] . Furthermore, these compounds labelled with positron-emitting radioisotopes can be used as in situ reporter probes to allow non-invasive imaging of HSV-1 TK gene expression using positron emission tomography (PET) [22] [23] [24] [25] . The pronounced biological activities exhibited by C-6 substituted pyrimidine derivatives provide a good rationale for further exploration of the chemistry and biological activities of these compounds [26] [27] [28] [29] [30] . Thus, we have synthesized nucleoside mimetics in which acyclic sugar moiety is attached at the C-6 position. Some C-6 fluoroalkylated pyrimidines exhibited pronounced cytostatic activities [31] [32] [33] , while thymines with 6-(2,3-dihydroxypropyl) and 6-(1,3-dihydroxyisobutyl) side-chains have been developed as tracer molecules for monitoring of HSV-1 TK expression by means of PET [34] [35] [36] . Our investigations were prompted by the need to develop PET imaging agents which lack the disadvantages of already existing reporter probes of HSV-1 TK, such as 9-[4-[
18 F]fluoro-3-(hydroxymethyl)butyl]guanine ([ 18 F]FHBG) which shows cytotoxicity and unfavorable pharmaco-kinetics [37] . In our previous work we described the compound 6-(1,3-dihydroxyisobutyl)thymine (DHBT) and discussed its advantages over existing compounds [35] . The molecular modeling and the X-ray structure of HSV-1 TK in complex with N-methylated DHBT gave new insights for the design and synthesis of further C-6 substituted pyrimidine derivatives with differentiated pharmacokinetics [37] . In the view of the facts mentioned above and in continuation of our previous work on development of tracer molecules for non-invasive imaging of gene expression using PET, we have now prepared new N-methoxymethylated (MOM) C-6 acyclic pyrimidine derivatives. Thus, herein we report syntheses of novel N-1-and/or N-3-MOM pyrimidines 4−13 and pyrimidin-2,4-diones 15−17 bearing C-6 isobutyl side-chains, as well as a bicyclic pyrimido [1,6-c] [1, 3] oxazepine derivative 14.
Results and Discussion

Chemistry
Synthesis of the pyrimidine scaffold 2 was achieved according to the previously reported procedure (Scheme 1) [38] . Treatment of 2,4-dimethoxy-5,6-dimethylpyrimidine with lithium diispropylamide (LDA) in THF at −55 °C afforded the corresponding lithiated precursor, which reacted in situ with 1,3-dibenzyloxy-2-propanone to give 6-(1,3-dibenzyloxy-2-hydroxyisobutyl)thymine (1) [35] . The lithiation reaction has been method for introducing various functionalities into the pyrimidine moiety [39] . Reaction of 1 with methyl oxalyl chloride gave oxalate, which was submitted to Barton-McCombie deoxygenation using tributyltin hydride and 2,2'-azobis(isobutyronitrile). This is radical substitution in which ester group in oxalate is replaced by a hydride to give pyrimidine derivative containing 3-benzyloxy-2-(benzyloxymethyl)propyl side-chain (2) .
Hydrolysis of the 2,4-dimethoxy group in 2 was accomplished with trimethylsilyl iodide generated in situ from trimethylsilyl chloride and sodium iodide to afford pyrimidin-2,4-dione 3 in 18% yield (Scheme 1). Demethoxylation of 2 with acetyl chloride (AcCl) and water gave the same product 3 in improved yield (68%). To avoid intramolecular cyclization and formation of a conformationally constrained carbon-bridged pyrrolido[1,2-c]pyrimidine, formed by N-1 linkage to the acyclic moiety at C-6 position [35, 38] , a strategy involving N-methoxymethylation of 3 was applied with methoxymethyl chloride (MOMCl) as alkylating reagent. As the literature precedents attest [40] [41] [42] [43] [44] there are only a few reports on the MOM protection of nitrogen in a pyrimidine ring, and no report of N-MOM derivatives with C-6 isobutyl side-chains. Generally, N-methoxymethylation is accomplished by the substitution of MOMCl with activated O-persilylated or N-anionic uracil derivatives. In our method A chlorotrimethylsilane (TMSCl) was applied as a silylating agent and the reaction was conducted in CH 3 Table 1 .
Debenzylation of 4 was carried out using boron trichloride to afford N,N-1,3-diMOM (7) with 6-(1,3-dihydroxyisobutyl) side-chain as major product (33.4% yield). However, N-1 and N-3 deprotection of 4 also occurred during this reaction and N-1-MOM (8) and N-3-MOM (9) pyrimidine derivatives as a mixture of regioisomers in ratio 3:1 were isolated (Scheme 2). N,N-1,3-diMOM-pyrimidine 7 was subsequently treated with 4-methoxytrityl chloride (MTrCl) to afford both ditritylated (compound 10) and monotritylated (compounds 11 and 12) pyrimidine derivatives. Fluorination of ditritylated compound 10 with diethylaminosulfur trifluoride (DAST) as the fluorinating reagent and subsequent in situ deprotection of trytl group by using HCl (5%) gave N,N-1,3-diMOM pyrimidines with 1-fluoro-3-hydroxyisobutyl-(compound 13) and 1,3-dihydroxyisobutyl (compound 7) side-chains. The bicyclic compound 14, was also obtained as an intramolecular cyclization product of 13 [45] . Interestingly, unexpected N-deprotection during debenzylation of 4 and tritylation of 7 occurred while in the detritylation reaction using HCl (5%) the MOM group was unreactive. The tosylation reaction of 11 and 12 did not afford the pyrimidine derivative with a 6-(1-methoxytrityl-3-tosylisobutyl) side-chain that could be used as the precursor for radiochemical synthesis. Debenzylation of 5 accompained by N-1 demethoxymethylation afforded both N-1-MOM pyrimidine derivative (8) 
Scheme 2. Syntheses of pyrimidine derivatives 7-14.
Reagents and conditions: (i)
BCl
NMR Studies
The chemical identities of compounds 2−17 were confirmed by 
to N-1 of pyrimidine ring. Similarly, the methylene protons of the N-1-MOM group (δ 5.34 ppm) in 7 showed NOESY correlations with the H-1' protons (δ 2.70 ppm), whereas the N-3-MOM group showed only NOE enhancements amongst the methoxymethyl protons. NOE cross-peaks between the phenyl ring (OMTr) and the CH 3 -5 group were observed in 12, whereas the H-3" hydroxymethyl protons (δ 3.68 and 3.84 ppm) showed NOESY correlation signals with the N-1-MOM group (δ 5.34 ppm). These NOE enhancements suggested that predominant conformation of 12 possessed the hydroxymethyl group closer to the N-1-MOM functionality, whereas the OMTr was in proximity to the CH 3 -5 group (Figure 1 ). NOE enhancements were observed between the methylene protons of the N-1-MOM group (δ 5.28 ppm) and H-1' (δ 2.72 ppm) as well as H-2' (δ 2.10 ppm) in 13. No NOE enhancements were observed between the N-1-MOM group and the hydroxymethyl or fluoromethyl protons, which suggests a nonrestricted rotation along the C-6 acyclic side-chain in 13. Conformational study of compounds 5, 6, 7, 10 and 16, which bear identical substituents attached to C2', showed only trivial NOESY cross-peaks. Consequently, no particular conformational preferences could be established for these compounds. 
Experimental
General
All solvents were dried/purified following recommended drying agents and/or distilled over 3 Å molecular sieves. For monitoring the progress of a reaction and for comparison purposes, thin layer chromatography (TLC) was performed on pre-coated Merck silica gel 60F-254 plates using an appropriate solvent system and the spots were detected under UV light (254 nm). For column chromatography silica gel (Fluka, 0.063-0.2 mm) was employed, glass column was slurry-packed under gravity and eluents were CH 2 
6-[(3-Benzyloxy
Method A: To a solution of dry 3 (33.7 mg, 0.085 mmol) in anhydrous CH 3 CN (2 mL) TMSCl (0.03 mL, 0.256 mmol) was added and reaction mixture was refluxed for 2 h. Then reaction mixture was cooled to r.t. and MOMCl (0.017 mL, 0.214 mmol) and (iPr) 2 EtN (0.037 mL, 0.214 mmol) were added. Stirring at 50 °C was continued for 6 h. Solvent was evaporated to dryness and residue was purified by column chromatography (CH 2 Cl 2 -MeOH = 30:1) to give oily products 4 (9.2 mg, 22.4%), 5 (5 mg, 13.4%) and 6 (4.1 mg, 11%).
Method (6 
6-[(3-Benzyloxy-2-benzyloxymethyl)propyl]-1,3-dimethoxymethyl-5-methyl-pyrimidin-2,4-dione
6-[(3-Benzyloxy-2-benzyloxymethyl)propyl]-1-methoxymethyl-5-methylpyrimidin-2,4-dione (5
6-[(3-Benzyloxy-2-benzyloxymethyl)propyl]-3-methoxymethyl-5-methylpyrimidin-2,4-dione
6-[(3-Hydroxy-2-hydroxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione (7), 6-[(3-hydroxy-2-hydroxymethyl)propyl]-1-methoxymethyl-5-methylpyrimidin-2,4-dione (8) and 6-[(3-hydroxy-2-hydroxymethyl)propyl]-3-methoxymethyl-5-methylpyrimidin-2,4-dione (9)
A solution of dry 4 (122.3 mg, 0.253 mmol) in anhydrous CH 2 Cl 2 (6.4 mL) was cooled to −78 °C with exclusion of moisture and BCl 3 (1 mL, 1M in CH 2 Cl 2 ) was added under Ar atmosphere. The reaction mixture was stirred at −70 °C for 1 h and quenched by the addition of CH 2 Cl 2 /MeOH solution (1:1, 10 mL) and evaporated to dryness. Purification by column chromatography (CH 2 Cl 2 -MeOH = 10:1) gave 7 as an oil (25.7 mg, 33.4%) and 8 and 9 as a mixture of N-1 and N-3 regioisomers in a 3:1 ratio (16.2 mg, 24 .8%). 43 .93 (C-2'), 26 .93 (C-1'), 11.50 (CH 3 -5). 
6-[(3-Hydroxy-2-hydroxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione (7
6-[(3-Hydroxy-2-hydroxymethyl)propyl]-3-methoxymethyl-5-methylpyrimidin-2,4-dione (9
6-[2,3-Bis(4-methoxytriphenylmethoxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione (10), 6-[3-hydroxy-2-(4-methoxytriphenylmethoxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione (11) and 6-[3-hydroxy-2-(4-methoxytriphenylmethoxymethyl)propyl]-1-methoxymethyl-5-methylpyrimidin-2,4-dione (12)
A solution of 7 (23.7 mg, 0.078 mmol) and DMAP (0.2 mg, 0.0016 mmol) in DMF (0.5 mL) and Et 3 N (0.04 mL) was cooled to 0 °C and after 10 minutes MTrCl (60.52 mg, 0.196 mmol) was added. Obtained mixture was additionally stirred at r.t. overnight and solvent was evaporated. Further purification by column chromatography (initial eluent CH 2 Cl 2 -CH 3 OH = 50:1, then CH 2 Cl 2 -CH 3 OH = 10:1) afforded gray crystals of 10 (32 mg, 46.4%, m.p. = 101-102 °C), yellow powder of 11 (16.9 mg, 37.5%, m.p. = 57-59 °C) and white powder of 12 (2.3 mg, 5.5%, m.p. = 94-96 °C). [1,6-c] [1, 3] oxazepine-7,9-dione (14) A solution of dry 10 (30 mg, 0.037 mmol) in anhydrous CH 2 Cl 2 (8 mL) was cooled to −78 °C and stirred for 15 min under Ar atmosphere. DAST (0.05 mL) was added dropwise and reaction was kept at −78 °C for additional 15 min after which cooling bath was removed. After 5 h of stirring at r.t., saturated aqueous solution of NaHCO 3 (10 mL) was added and reaction was partitioned. Organic layer was separated, dried over MgSO 4 and evaporated to dryness. Raw product was then dissolved in CH 3 OH (0.5 mL) and 5% HCl (0.7 mL) and refluxed for 15 min. Solvent was evaporated and residue was purified by column chromatography (CH 2 Cl 2 -CH 3 OH = 30:1) to afford 13 (1.2 mg, 10.7%), 7 (3.6 mg, 32.2%) and 14 (3.1 mg, 31%). 
6-[2,3-Bis(4-methoxytriphenylmethoxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione
6-[3-Hydroxy-2-(4-methoxytriphenylmethoxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione (11
6-[(3-Fluoro-2-hydroxymethyl)propyl]-1,3-dimethoxymethyl-5-methylpyrimidin-2,4-dione (13
6-[3-Hydroxy-2-(4-methoxytriphenylmethoxymethyl)propyl]-5-methylpyrimidin-2,4-dione (17)
. 
Conclusions
In summary, we have adopted simple and efficient methods for the protection and deprotection of the carbonyl and nitrogen moieties in a pyrimidine ring, as well as hydroxyl groups in a C-6 isobutyl side-chain under mild conditions in moderate to excellent yields. The methoxymethyl (MOM) moiety as protecting group was introduced using different synthetic methods radiolabelling that contains appropriate leaving groups, introduction of mesylate, instead of tosylate, as less bulky group is foreseen.
